Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system Journal Article


Authors: Avanzi, M. P.; Yeku, O.; Li, X.; Wijewarnasuriya, D. P.; van Leeuwen, D. G.; Cheung, K.; Park, H.; Purdon, T. J.; Daniyan, A. F.; Spitzer, M. H.; Brentjens, R. J.
Article Title: Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system
Abstract: Chimeric antigen receptor (CAR) T cell therapy has proven clinically beneficial against B cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. However, suboptimal clinical outcomes have been associated with decreased expansion and persistence of adoptively transferred CAR T cells, antigen-negative relapses, and impairment by an immunosuppressive tumor microenvironment. Improvements in CAR T cell design are required to enhance clinical efficacy, as well as broaden the applicability of this technology. Here, we demonstrate that interleukin-18 (IL-18)-secreting CAR T cells exhibit enhanced in vivo expansion and persistence and significantly increase long-term survival in syngeneic mouse models of both hematological and solid malignancies. In addition, we demonstrate that IL-18-secreting CAR T cells are capable of modulating the tumor microenvironment, as well as enhancing an effective endogenous anti-tumor immune response. IL-18-secreting CAR T cells represent a promising strategy to enhance the clinical outcomes of adoptive T cell therapy. Avanzi et al. generate CAR T cells that secrete IL-18 and show improved activity in syngeneic hematologic and solid tumor models without prior preconditioning. They further show enhanced recruitment and anti-tumor activity of endogenous T cells. © 2018 The Authors
Keywords: ovarian cancer; chimeric antigen receptor; adoptive transfer; muc16; interleukin-18; il-18; car t cell; armored car; b-all
Journal Title: Cell Reports
Volume: 23
Issue: 7
ISSN: 2211-1247
Publisher: Cell Press  
Date Published: 2018-05-15
Start Page: 2130
End Page: 2141
Language: English
DOI: 10.1016/j.celrep.2018.04.051
PROVIDER: scopus
PUBMED: 29768210
PMCID: PMC5986286
DOI/URL:
Notes: Article -- Export Date: 1 June 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Renier J Brentjens
    286 Brentjens
  2. Terence John Purdon
    61 Purdon
  3. Kenneth   Cheung
    10 Cheung
  4. Oladapo Olumoroti Yeku
    16 Yeku
  5. Anthony   Daniyan
    31 Daniyan
  6. Mauro Pellegrino Avanzi
    3 Avanzi
  7. Hyebin Park
    2 Park